Gan & Lee Pharmaceuticals
SSE:603087
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
33.1
52.65
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals
Revenue
Gan & Lee Pharmaceuticals
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Gan & Lee Pharmaceuticals
SSE:603087
|
Revenue
¥2.6B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Revenue
¥17.4B
|
CAGR 3-Years
102%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Revenue
¥7.5B
|
CAGR 3-Years
16%
|
CAGR 5-Years
84%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Revenue
¥5.5B
|
CAGR 3-Years
33%
|
CAGR 5-Years
41%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Revenue
¥36.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
31%
|
CAGR 10-Years
47%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Revenue
¥2.9B
|
CAGR 3-Years
59%
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
Gan & Lee Pharmaceuticals
Glance View
Gan & Lee Pharmaceuticals, a notable player in the realm of biopharmaceuticals, has carved a niche for itself largely in the field of insulin production. Founded in China, the company embarked on a mission to innovate and deliver quality healthcare solutions, particularly in the fight against diabetes. From its inception, Gan & Lee made significant strides in biotechnology, focusing on human insulin analogues—a sophisticated field that requires precise engineering and scientific prowess. The company has established a robust portfolio of insulin products, which include fast-acting, long-acting, and mixed formulations designed to meet the diverse needs of diabetic patients. By leveraging advanced manufacturing techniques and adhering to stringent quality standards, Gan & Lee ensures that its offerings are competitive both in efficacy and cost-effectiveness. Revenue generation at Gan & Lee is intricately tied to its ability to scale production and distribution across emerging and established markets. This means not only mastering the science behind their products but also navigating the complex regulatory landscapes of different countries. The company's expertise extends to research and development, where it continues to invest heavily in exploring new therapeutics beyond insulin to diversify its pharmaceutical portfolio. Collaborations with global partners also fuel Gan & Lee's growth, facilitating market access and expanding its footprint beyond Asia. By balancing innovation with strategic alliances, Gan & Lee sustains its position in the healthcare sector, generating solid returns while impacting public health on a broad scale.
See Also
What is Gan & Lee Pharmaceuticals's Revenue?
Revenue
2.6B
CNY
Based on the financial report for Dec 31, 2023, Gan & Lee Pharmaceuticals's Revenue amounts to 2.6B CNY.
What is Gan & Lee Pharmaceuticals's Revenue growth rate?
Revenue CAGR 5Y
2%
Over the last year, the Revenue growth was 52%. The average annual Revenue growth rates for Gan & Lee Pharmaceuticals have been -8% over the past three years , 2% over the past five years .
You don't have any saved screeners yet
